Modulating Oxytocin Activity and Plasma Stability by Disulfide Bond Engineering

Journal of Medicinal Chemistry
2010.0

Abstract

Disulfide bond engineering is an important approach to improve the metabolic half-life of cysteine-containing peptides. Eleven analogues of oxytocin were synthesized including disulfide bond replacements by thioether, selenylsulfide, diselenide, and ditelluride bridges, and their stabilities in human plasma and activity at the human oxytocin receptor were assessed. The cystathionine (K(i) = 1.5 nM, and EC₅₀ = 32 nM), selenylsulfide (K(i) = 0.29/0.72 nM, and EC₅₀ = 2.6/154 nM), diselenide (K(i) = 11.8 nM, and EC₅₀ = 18 nM), and ditelluride analogues (K(i) = 7.6 nM, and EC₅₀ = 27.3 nM) retained considerable affinity and functional potency as compared to oxytocin (K(i) = 0.79 nM, and EC₅₀ = 15 nM), while shortening the disulfide bridge abolished binding and functional activity. The mimetics showed a 1.5-3-fold enhancement of plasma stability as compared to oxytocin (t(½) = 12 h). By contrast, the all-D-oxytocin and head to tail cyclic oxytocin analogues, while significantly more stable with half-lives greater than 48 h, had little or no detectable binding or functional activity.

Knowledge Graph

Similar Paper

Modulating Oxytocin Activity and Plasma Stability by Disulfide Bond Engineering
Journal of Medicinal Chemistry 2010.0
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs
Bioorganic & Medicinal Chemistry 2018.0
Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6
Journal of Medicinal Chemistry 1976.0
Synthesis and Pharmacology of Novel Analogues of Oxytocin and Deaminooxytocin:  Directed Methods for the Construction of Disulfide and Trisulfide Bridges in Peptides<sup>,</sup><sup>,</sup>
Journal of Medicinal Chemistry 1997.0
Structure-Based Design of Glycosylated Oxytocin Analogues with Improved Selectivity and Antinociceptive Activity
ACS Medicinal Chemistry Letters 2023.0
Replacement of the disulfide bond in oxytocin by an amide group. Synthesis and some biological properties of [cyclo-(1-L-aspartic acid, 6-L-.alpha.,.beta.-diaminopropionic acid)]oxytocin
Journal of Medicinal Chemistry 1978.0
Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7
European Journal of Medicinal Chemistry 2007.0
Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid),4-threonine]oxytocin (hydroxy[4-thr]oxytocin), a peptide with strikingly high oxytocic potency, and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-oxytocin)
Journal of Medicinal Chemistry 1976.0
Dicarbavasopressin antagonist analogs exhibit reduced in vivo agonist activity
Journal of Medicinal Chemistry 1988.0
Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception
Journal of Medicinal Chemistry 2020.0